0QKQ Stock Overview
A biopharmaceutical company, focuses on identification, development, and commercialization of novel, patent protected products for the treatment of rare metabolic, dermatological, and pulmonary diseases in Switzerland, Europe, North America, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Relief Therapeutics Holding SA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CHF 5.02 |
| 52 Week High | CHF 7.56 |
| 52 Week Low | CHF 1.06 |
| Beta | -14.81 |
| 11 Month Change | -13.45% |
| 3 Month Change | 358.45% |
| 1 Year Change | 164.21% |
| 33 Year Change | -77.10% |
| 5 Year Change | n/a |
| Change since IPO | -96.04% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0QKQ | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | -23.0% | -5.2% | 0.8% |
| 1Y | 164.2% | -20.1% | 6.6% |
Return vs Industry: 0QKQ exceeded the UK Biotechs industry which returned -18.9% over the past year.
Return vs Market: 0QKQ exceeded the UK Market which returned 6.1% over the past year.
Price Volatility
| 0QKQ volatility | |
|---|---|
| 0QKQ Average Weekly Movement | 29.3% |
| Biotechs Industry Average Movement | 9.6% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in GB Market | 10.3% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: 0QKQ's share price has been volatile over the past 3 months compared to the UK market.
Volatility Over Time: 0QKQ's weekly volatility has increased from 17% to 29% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | 49 | n/a | www.relieftherapeutics.com |
Relief Therapeutics Holding SA, a biopharmaceutical company, focuses on identification, development, and commercialization of novel, patent protected products for the treatment of rare metabolic, dermatological, and pulmonary diseases in Switzerland, Europe, North America, and internationally. The company offers SETOFILM/ONDISSOLVE for radiotherapy induced nausea and vomiting, and chemotherapy induced nausea and vomiting, as well as postoperative induced nausea and vomiting; OLPRUVA, a sodium phenylbutyrate for the treatment of urea cycle disorders, and maple syrup urine disease; and PKU GOLIKE for for the dietary management of phenylketonuria. It also develops TYR GOLIKE, that has completed Phase III clinical trial to treat Tyrosinemia; and RLF-100, a synthetic form of vasoactive intestinal peptide (VIP), that is in Phase II clinical trial for the treatment of acute respiratory distress syndrome (ARDS) associated with COVID-19 related ARDS and in preclinical trial to treat pulmonary sarcoidosis, checkpoint inhibitor-induced pneumonitis, and chronic berylliosis.
Relief Therapeutics Holding SA Fundamentals Summary
| 0QKQ fundamental statistics | |
|---|---|
| Market cap | CHF 66.46m |
| Earnings (TTM) | -CHF 46.24m |
| Revenue (TTM) | CHF 8.60m |
7.7x
P/S Ratio-1.4x
P/E RatioIs 0QKQ overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0QKQ income statement (TTM) | |
|---|---|
| Revenue | CHF 8.60m |
| Cost of Revenue | CHF 2.70m |
| Gross Profit | CHF 5.90m |
| Other Expenses | CHF 52.13m |
| Earnings | -CHF 46.24m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.69 |
| Gross Margin | 68.56% |
| Net Profit Margin | -537.79% |
| Debt/Equity Ratio | 0.02% |
How did 0QKQ perform over the long term?
See historical performance and comparison